(£) www.thetimes.com/uk/healthcar...
(£) www.thetimes.com/uk/healthcar...
www.lbc.co.uk/article/alzh...
www.lbc.co.uk/article/alzh...
https://www.stocktitan.net/news/IONS/diranersen-demonstrates-increasing-clinical-benefit-at-two-years-in-renzvefnqnxf.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IONS/diranersen-demonstrates-increasing-clinical-benefit-at-two-years-in-renzvefnqnxf.html?utm_source=stocktitan-bluesky&utm_medium=social
🧠 Biogen reports two-year CELIA data on diranersen.
⚠️ Anthropic founders warn of authoritarian AI surveillance.
🧠 Biogen reports two-year CELIA data on diranersen.
⚠️ Anthropic founders warn of authoritarian AI surveillance.
Caveats: it missed its phase 2 main goal and isn't approved. Phase 3 is planned.
#Alzheimers #Science
Caveats: it missed its phase 2 main goal and isn't approved. Phase 3 is planned.
#Alzheimers #Science
https://investors.biogen.com/news-releases/news-release-details/biogens-diranersen-demonstrates-increasing-clinical-benefit-two
https://investors.biogen.com/news-releases/news-release-details/biogens-diranersen-demonstrates-increasing-clinical-benefit-two
https://www.medpagetoday.com/meetingcoverage/ctad/123956
https://www.medpagetoday.com/meetingcoverage/ctad/123956
Biogenが、CTAD 2026でアルツハイマー病領域の新データを発表する。タウ標的のdiranersen(BIIB080)は第2相CELIA試験の96週長期延長データを出す。lecanemabはClarity AD非盲検延長の5年間データと、LEADER試験の3年間実臨床データを示す。Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
stellanews.life/technology/1...
Biogenが、CTAD 2026でアルツハイマー病領域の新データを発表する。タウ標的のdiranersen(BIIB080)は第2相CELIA試験の96週長期延長データを出す。lecanemabはClarity AD非盲検延長の5年間データと、LEADER試験の3年間実臨床データを示す。Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
stellanews.life/technology/1...